drugset / Trial / NCT00105183
EZ-2053 in the Prophylaxis of Acute Pulmonary Allograft Rejection
RandomizedParallel-groupQuadruple-blindPrevention
Summary
The purpose of this study is to assess the efficacy and safety of the study drug, known as "ATG Fresenius S," which is sometimes called "EZ-2053," to prevent a lung transplant patient's body from rejecting a transplanted lung or lungs.
Timeline
- Start
- 2005-01
- Primary completion
- 2010-01
- Completion
- 2011-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Thymoglobulin | Protein / enzyme biologic | 5 mg/kg | Intravenous |
| Comparator | Thymoglobulin | Protein / enzyme biologic | 9 mg/kg | Intravenous |